Business
Clinical findings published in Diabetologia
Clinical findings published in Diabetologia.
About this update from Renalytix Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 4091U\n Renalytix AI PLC\n 06 April 2021\n \n \n \n \n \n \n \n \n \n \n Renalytix AI plc\n \n \n \n (\"RenalytixAI\" or the \"Company\")\n \n \n \n \n \n \n Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure\n \n \n \n \n \n Clinical findings published in the April issue of Diabetologia, the official journal \n \n \n of the European Association for the Study of Diabetes\n \n \n \n \n \n \n NEW YORK, April 6, 2021\n \n - \n \n \n RenalytixAI plc\n \n \n (LSE: RENX) (NASDAQ: RNLX), announced today that \n \n \n KidneyIntelX™\n \n \n more accurately predicted progressive kidney function decline and kidney failure in a multi-center, diverse cohort of 1,146 type 2 diabetes patients with early-stage (stages 1, 2, and 3) kidney disease versus the current standard of care. The results of the study, which is the second peer-reviewed clinical validation study on KidneyIntelX, have been published in \n \n \n Diabetologia\n \n \n , the official journal of the \n \n \n European Association for the Study of Diabetes\n \n \n (EASD).\n \n \n \n \n \n Strong performance of the KidneyIntelX platform is attributed in part to its proprietary, blood-based biomarker technologies, exclusively licensed from the Joslin Diabetes Center and the Mount Sinai Health System.\n \n \n \n \n \n Notably, KidneyIntelX was observed to be highly effective at both ends of the risk spectrum. In the study, KidneyIntelX more accurately identified and segmented patients into three risk categories (low, intermediate and high) when compared to clinical models, including the current standard of care, the KDIGO risk stratification algorithm. When guideline-recommended urine albumin to creatinine ratio testing was performed, the positive predictive value (PPV) for progressive decline in kidney function was 69% for those scored as high-risk by KidneyIntelX versus the 40% identified as highest-risk by KDIGO categorization. This is a 72% improvement compared to standard of care. In addition, only 7% of those scored as low-risk by KidneyIntelX experienced progression (i.e., negative predictive value of 93%). \n \n \n \n \n \n \"Dia...